时间分辨简介（Time resolved profile）.docVIP

时间分辨简介（Time resolved profile） Second Military Medical University Changzheng Hospital Zhao Kekai, Miu Xiaohui, http://91mm.us/ In the latest issue of the American Journal of Hepatology (Hepatology) published a review of Robert Periro (Robert P. Perrillo), the full text of the compiler, for your reference. In hepatitis B treatment, removal of HBsAg is expected to be the closest indicator of clinical cure. The conclusion comes from the natural history of hepatitis B, the liver cirrhosis patients who have been cleared of HBsAg, with longer stays, lower liver decompensation, and a lower incidence of hepatocellular carcinoma. Molecular biological methods, such as real-time quantitative PCR, showed that the DNA was very low in patients with HBsAg (0.002 copies / hepatocytes). It can also explain the reasons for the low rate of reactivation of hepatitis B in patients with anti -HBc positive and HBsAg negative malignant tumors during chemotherapy. Although the clinical importance of HBsAg clearance is becoming increasingly important, it has not been considered the primary endpoint in the treatment trials because of its low incidence. Many studies have shown that HBsAg clearance rates are similar to natural clearance rates even with extended nucleoside analogues (the annual natural clearance rate is 1% to 2% in Western HBV carriers and 0.5% to 1% in Asian carriers). Although interferon treatment may remove HBsAg, 6~12 months after the end of the treatment, the evaluation showed that only a small number of patients achieved this effect. It is reported that the rate of HBsAg disappearance in patients with HBeAg positive interferon treatment is 3% to 10%, which is not clearly related to the length of treatment, while in HBeAg negative patients, the rate of HBsAg disappearance is lower, The patients persistent virologic response rate (SVR) is usually low, too. Marcellin and colleagues recently reported a 3% loss of HBsAg in a large cohort study of pegylated interferon alpha -2a a